1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

 
• By Eileen Francis

Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.

Harm Reduction Therapeutics Inc. estimates the first Rx-to-OTC switch for naloxone could hit the US market within 18 to 24 months, thanks to a $3.42m grant provided by opioid drug maker Purdue Pharma LP.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

Cosmetics Europe Argues Against Potential Ban Of Common Fragrance, Cosmetic Ingredient Ethanol

 
• By Eileen Francis

Cosmetics Europe is working to obtain derogations for three fragrance and/or cosmetic substances that may be categorized as carcinogenic, mutagenic or reprotoxic, which could result in a ban of their use under the Cosmetic Products Regulation.

US Tariffs: Fragrance Industry Pushes For Exclusion Of Non-US Cultivated Materials, On Top Of Current Exemptions

 
• By Eileen Francis

Fragrance Creators Association will push the Trump Administration to exclude from tariffs fragrance materials that cannot be produced or cultivated domestically, while both FCA and the Personal Care Products Council will continue to promote the economic benefits of their respective industries.

Oregon EPR Reporting Deadline Passes, But Non-Compliant Firms Have One More Shot

 
• By Eileen Francis

Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.

German Industry Urges ECHA To Reconsider ‘De Facto’ EU Ethanol Ban

 
• By David Ridley

Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.

More from Policy & Regulation

Oregon EPR Reporting Deadline Passes, But Non-Compliant Firms Have One More Shot

 
• By Eileen Francis

Single-use packaging producers subject to Oregon state’s Extended Producer Responsibility law that didn’t meet the 31 March deadline to report their packaging materials are given a grace period to report until 30 April, says Circular Action Alliance, the organization carrying out the EPR program.

German Industry Urges ECHA To Reconsider ‘De Facto’ EU Ethanol Ban

 
• By David Ridley

Reclassifying ethanol as a carcinogenic, mutagenic, or reprotoxic substance - something the European Chemicals Agency seems likely to do in the near future - would be “tantamount to a de facto ban” with “fatal consequences” for medical care in Germany, says Pharma Deutschland in a joint paper with 13 other German healthcare industry associations.

CA Prop 65: Personal Care Firms Wrestle With Listing Of Common Stabilizer, Packaging Material

 
• By Eileen Francis

Personal care companies selling in California that suspect they are subject to its listing of a common stabilizer and packaging material should collect Certificates of Analysis for all raw materials, pursue third-party formula testing and retain counsel.